Biosimilars in the United States 2020–2024, IQVIA Institute Report. September 29, 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024
March 2021 Report to Congress on Medicaid and CHIP, MEDPAC, March 2021. https://www.medpac.gov/wp-content/uploads/2021/10/mar21_medpac_report_ch13_sec.pdf
Study: Medicare’s Lost Savings Due to Delayed Adalimumab Biosimilar Entry, By Tony Hagen, Center for Biosimilars. July 12, 2021. https://www.centerforbiosimilars.com/view/study-medicare-s-lost-savings-due-to-delayed-adalimumab-biosimilar-entry
March 2021 Report to Congress on Medicaid and CHIP, MEDPAC, March 2021. https://www.medpac.gov/wp-content/uploads/2021/10/mar21_medpac_report_ch13_sec.pdf
Medicare Part D and Beneficiaries Could Realize Significant Spending Reductions With Increased Biosimilar Use, U.S. Department of Health and Human Services Office of Inspector General. March 29, 2022. https://oig.hhs.gov/oei/reports/OEI-05-20-00480.asp